Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors.

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Turning pain into purpose is the aim of a Northland ovarian cancer patient, who hopes a song about her cancer fight will ...